CGTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	133 327
Average Volume	202 319
Market Cap	75.27M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $-0.230 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.24
ATR14	$0.0170 (0.88%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-14	Ricciardi Lisa	Buy	5 700	Common Stock
2024-02-15	Doyle John Brendan	Buy	20 000	Common Stock
2024-02-15	Doyle John Brendan	Buy	20 000	Stock Option (Right to Buy)
2024-02-15	Caggiano Anthony	Buy	60 000	Common Stock
2024-02-15	Caggiano Anthony	Buy	60 000	Stock Option (Right to Buy)

INSIDER POWER
97.06
Last 94 transactions
Buy: 12 730 714 \| Sell: 1 480 989

Volume Correlation

Long: 0.01 (neutral)

Short: 0.63 (weak)

Signal:(51.274) Neutral

Cognition Therapeutics, Correlation

10 Most Positive Correlations
BOWXU	0.909
AYLA	0.897
AGCUU	0.896
ASPS	0.896
IRBT	0.894
ARQQ	0.878
AMD	0.876
CELU	0.875
OP	0.873
SNPS	0.872

10 Most Negative Correlations
IVAC	-0.894
ULTA	-0.889
ISEM	-0.884
PAHC	-0.882
CTLP	-0.879
RCM	-0.877
WFRD	-0.876
STAY	-0.872
IQ	-0.872
IDLB	-0.865

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cognition Therapeutics, Correlation - Currency/Commodity

0.55
( weak )

0.58
( weak )

0.00
( neutral )

0.79
( moderate )

-0.48
( neutral )

0.50
( neutral )

Cognition Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-252 000 (0.00 %)
EPS:	$-0.860

Q4	2023
Revenue:	$0
Gross Profit:	$-66 000.00 (0.00 %)
EPS:	$-0.260

Q3	2023
Revenue:	$0
Gross Profit:	$-65 000.00 (0.00 %)
EPS:	$-0.220

Q2	2023
Revenue:	$0
Gross Profit:	$-61 000.00 (0.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Cognition Therapeutics,

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.